Suppliers and packagers for VIIBRYD

VIIBRYD

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567	NDA	Allergan, Inc.	0456-1110-30	30 TABLET in 1 BOTTLE (0456-1110-30)	2011-04-29
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567	NDA	Allergan, Inc.	0456-1120-30	30 TABLET in 1 BOTTLE (0456-1120-30)	2011-04-29
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567	NDA	Allergan, Inc.	0456-1140-30	30 TABLET in 1 BOTTLE (0456-1140-30)	2011-04-29

VIIBRYD suppliers: APIs, finished-dose manufacturers, and contract partners for vilazodone

Last updated: May 26, 2026

Executive summary: Viibryd (vilazodone) is a branded oral antidepressant (vilazodone hydrochloride). Published supplier visibility is strongest for the finished-dose manufacturing network and the corporate owners listed on FDA labeling and compendial records; however, a complete, audit-ready “supplier for every component” map (API source, excipient suppliers, and all toll-packagers) is not publicly determinable from the standard open datasets typically used for pharmaceutical supply-chain due diligence. This limits the ability to produce a complete list of named suppliers for VIIBRYD.

What companies supply VIIBRYD (vilazodone) finished-dose tablets?

The key practical answer for “suppliers” in branded oral solids is usually the finished-dose manufacturer(s) and labeler of record on the US market packaging and FDA-facing documentation. For Viibryd, the labeler/manufacturer is the starting point for identifying contract manufacturing and secondary packaging partners, but it does not automatically enumerate API suppliers.

Labeling and US supply chain visibility for Viibryd tablets

• Viibryd is supplied as oral tablets (solid dosage form).
• Public-facing supplier identification generally comes from:
  • FDA label “Manufactured for / Distributed by” sections
  • Product listing records (NDC-level manufacturer and labeler metadata)
  • cGMP inspection databases (manufacturer-of-record, not necessarily API source)

What to expect in named “supplier lists”

• Finished-dose manufacturer(s): typically one or more US and/or non-US sites.
• Contract packager(s): can differ from the manufacturing site.
• API supplier(s): often not named in consumer-facing labeling; may be disclosed only in regulatory CMC filings or via company sourcing statements.

Which suppliers provide the vilazodone API used in VIIBRYD?

For API sourcing, the publicly verifiable supplier list is usually limited. For many branded small-molecule products, API vendors are not consistently named in labeling or Orange Book entries. Determining API suppliers typically requires:

• identification of the drug substance manufacturing site(s) listed in regulatory submissions, and/or
• procurement disclosures, DMF holder records, or direct supply-chain audits.

API identification constraints in public sources

• Orange Book entries are typically patent-centric, not supplier-centric.
• The US FDA “Active ingredient” listing supports drug substance identity at the molecule level, not the named manufacturing organization for the API.
• DMF or Drug Substance Master File references can be non-public at the “vendor list” granularity unless specifically visible in the linked submission.

What contract manufacturing partners make VIIBRYD tablets?

Contract manufacturing partner identification depends on matching:

• the manufacturing site shown on the marketed product label, and
• the cGMP manufacturing facility linked to the NDC presentation.

How finished-dose CMOs are typically identified

• NDC-level manufacturer/supplier metadata (where present)
• FDA inspection dataset facility names mapped to manufacturing role
• “Manufactured for” language on the commercial label

What “supplier” can mean in practice

In commercial negotiations, “supplier” can refer to:

• drug product manufacturer (tablet manufacturing and release),
• packager (blistering/bottling and labeling),
• API manufacturer (vilazodone HCl).

Only the first two are more consistently identifiable via public labeling and market listings.

What patents protect VIIBRYD and its commercial supply chain relevance?

“Supplier” and “patent estate” intersect because CMO and API vendor licensing depends on freedom-to-operate around:

• formulation and formulation-process IP,
• polymorphs and solid-state forms,
• manufacturing methods,
• use patents (dose regimens, indications).

How to interpret patent estate in supplier selection

• If formulation/process patents are active, suppliers are constrained by licensing or by using non-infringing manufacturing routes.
• If only use patents are active, generic manufacturing can proceed but may be constrained on labeling and prescribing.

Practical implication

Even where supplier identity is knowable, procurement decisions require patent clearance for the specific dosage form and process used by that supplier.

What generic or biosimilar entry risks affect VIIBRYD supply negotiations?

Vilazodone is a small molecule. The primary “entry risk” pathway is generic (ANDA) rather than biosimilar.

Generic entry mechanisms that change supply dynamics

• ANDA filings and potential Para IV challenges
• Patent expirations affecting which sites can manufacture
• Label carve-outs and settlement agreements affecting launch timing

Why it matters for suppliers

• If market exclusivity or patents remain, suppliers may prioritize incumbency pricing and continuity of supply.
• If barriers fall, suppliers can reallocate capacity to multiple brands, changing pricing and service levels.

What is the Orange Book status of VIIBRYD?

Orange Book listings include patents for:

• the active ingredient and approvals,
• and additional patents tied to formulation, use, and manufacturing.

This status is used to map:

• expiration windows,
• possible generic launch timing,
• and legal risk for any new supplier onboarding that touches the approved dosage form.

How Orange Book data is used for supplier due diligence

• Confirm which patents are listed for the specific Viibryd dosage strength(s).
• Match those patents to manufacturing and formulation scope.
• Screen supplier processes against likely protected features.

How do VIIBRYD competitors compare on supplier ecosystems?

Comparison is relevant because supplier ecosystems often mirror:

• common CMO networks for oral solids,
• overlapping excipient vendors,
• and shared API synthesis platforms.

Competitive angle

• If competitors source from the same tablet-manufacturing network, contracts may overlap.
• If competitors have different supplier networks, onboarding and qualification requirements can be distinct.

Key Takeaways

• “Suppliers for VIIBRYD” can mean drug product manufacturers, contract packagers, and API vendors; public records typically identify drug product/labeling parties more reliably than API vendors.
• A complete named supplier list for every supply-chain layer (API, excipients, packaging, release testing) is not consistently derivable from standard open public datasets.
• Patent estate and Orange Book status determine the legal and commercial feasibility of onboarding alternative suppliers for the approved vilazodone dosage forms.

FAQs

1) Who is the manufacturer of Viibryd tablets in the US?
The manufacturer is typically identified in the FDA label “Manufactured for / Distributed by” section and associated NDC listing metadata.

2) Does Orange Book list tablet manufacturing sites for Viibryd?
No. The Orange Book primarily lists patents tied to the approved application and labeling, not site-level CMO or API vendor identities.

3) Are vilazodone API suppliers listed publicly for Viibryd?
Often not in consumer-facing labeling; API vendor identities are usually visible only in regulatory submissions (CMC/DMF context) or via specific corporate disclosures.

4) What patents most often constrain generic supply of vilazodone tablets?
Formulation, manufacturing/process, and method-of-use patents tied to the specific approved dosage form and labeling.

5) What supplier risks matter when qualifying a new contract manufacturer for an oral antidepressant?
Regulatory alignment to the approved manufacturing process, solid-state/form control, impurity profile consistency, and patent-freedom-to-operate for the specific dosage strengths.

References

1. US FDA Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). https://www.accessdata.fda.gov/scripts/cder/daf/
2. DailyMed. Viibryd (vilazodone hydrochloride) prescribing information and product labeling. https://dailymed.nlm.nih.gov/